Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Hypothesis: Accept or Fail to Reject?01:17

Hypothesis: Accept or Fail to Reject?

The outcome of any hypothesis testing leads to rejecting or not rejecting the null hypothesis. This decision is taken based on the analysis of the data, an appropriate test statistic, an appropriate confidence level, the critical values, and P-values. However, when the evidence suggests that the null hypothesis cannot be rejected, is it right to say, 'Accept' the null hypothesis?
There are two ways to indicate that the null hypothesis is not rejected. 'Accept' the null hypothesis and 'fail to...
Clinical Trials01:16

Clinical Trials

Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
Trial and Error and Algorithm01:12

Trial and Error and Algorithm

A problem-solving strategy is a plan of action used to find a solution. Different strategies have distinct action plans. Trial and error involves trying different solutions until one works. For instance, to fix a broken printer, you might check ink levels, ensure the paper tray isn't jammed, and verify the printer's connection to your laptop. This method can be time-consuming but is commonly used. Thomas Edison, for example, used trial and error to find a suitable filament for the light bulb,...
Unrealistic Optimism Bias01:30

Unrealistic Optimism Bias

Unrealistic optimism bias is the tendency to overestimate the likelihood of positive outcomes. This cognitive bias makes individuals believe they are less likely to experience failures, setbacks, or risks and more likely to succeed than others. For example, people may assume they are less prone to health issues, accidents, or financial struggles than their peers, even when they share similar risk factors.One key component of this bias is the above-average effect, where individuals perceive...
What is a Hypothesis?01:14

What is a Hypothesis?

A hypothesis can be a simple sentence or statement about a property or any phenomenon observed or predicted for a population. It is usually a claim about a  property of the population. It can be stated for any field observations or experiments. A hypothesis statement cannot be said to be right or wrong as it is merely a statement. It needs to be tested through an elaborate data collection process and an appropriate statistical test. A hypothesis should be a general but not a vague statement. It...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Expert perspectives on de-escalation of antiplatelet therapy - Beyond the guidelines: Insights from the cardiovascular research technologies 2026 meeting.

Cardiovascular revascularization medicine : including molecular interventions·2026
Same author

Transcatheter vs surgical aortic valve implantation: age vs lifetime perspective.

European heart journal·2026
Same author

On the Noninferiority of Tirzepatide: Insights From SURPASS-CVOT.

Journal of the American College of Cardiology·2026
Same author

Current Incidence and Modality of Young Aortic Valve Replacement in the United States.

Circulation·2026
Same author

Expert perspectives on tricuspid repair | replacement | medical therapy - Beyond the Guidelines: Insights from the cardiovascular research technologies 2026 meeting.

Cardiovascular revascularization medicine : including molecular interventions·2026
Same author

M-TEER for Mitral Regurgitation: Does RESHAPE-HF2 Break the Tie or Muddy the Waters?

JACC. Cardiovascular interventions·2026

Related Experiment Video

Updated: May 30, 2026

An Experimental Analysis of Children's Ability to Provide a False Report about a Crime
07:36

An Experimental Analysis of Children's Ability to Provide a False Report about a Crime

Published on: May 3, 2016

The JUPITER trial: myth or reality?

Ryan P Morrissey1, George A Diamond, Sanjay Kaul

  • 1Cedars-Sinai Heart Institute, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA. ryan.morrissey@cshs.org

Current Atherosclerosis Reports
|July 27, 2011
PubMed
Summary

The JUPITER trial

Area of Science:

  • Cardiovascular Disease Prevention
  • Clinical Trial Analysis
  • Medical Research Methodology

Background:

  • The JUPITER trial investigated rosuvastatin for primary prevention of cardiovascular disease.
  • Landmark trials like JUPITER significantly influence medical practice and health policy.
  • Critical evaluation of trial design and execution is essential for accurate interpretation.

Purpose of the Study:

  • To address common myths and misunderstandings surrounding the JUPITER trial.
  • To critically analyze the limitations of the JUPITER trial's design and outcomes.
  • To explore the implications of these limitations on clinical decision-making and health policy.

Main Methods:

  • Review and critique of the JUPITER trial's methodology, focusing on patient selection and trial duration.

More Related Videos

Holistic Facial Composite Creation and Subsequent Video Line-up Eyewitness Identification Paradigm
09:49

Holistic Facial Composite Creation and Subsequent Video Line-up Eyewitness Identification Paradigm

Published on: December 24, 2015

JenaTron - An Experimental Approach to Study the Effects of Plant History and Soil History on Grassland Ecosystem Functioning
09:23

JenaTron - An Experimental Approach to Study the Effects of Plant History and Soil History on Grassland Ecosystem Functioning

Published on: March 21, 2025

Related Experiment Videos

Last Updated: May 30, 2026

An Experimental Analysis of Children's Ability to Provide a False Report about a Crime
07:36

An Experimental Analysis of Children's Ability to Provide a False Report about a Crime

Published on: May 3, 2016

Holistic Facial Composite Creation and Subsequent Video Line-up Eyewitness Identification Paradigm
09:49

Holistic Facial Composite Creation and Subsequent Video Line-up Eyewitness Identification Paradigm

Published on: December 24, 2015

JenaTron - An Experimental Approach to Study the Effects of Plant History and Soil History on Grassland Ecosystem Functioning
09:23

JenaTron - An Experimental Approach to Study the Effects of Plant History and Soil History on Grassland Ecosystem Functioning

Published on: March 21, 2025

  • Analysis of the impact of excluding patients with low high-sensitivity C-reactive protein (hsCRP) levels.
  • Examination of the consequences of early trial termination on benefit-risk and cost-effectiveness assessments.

    • Main Results:

    • Exclusion of patients with low hsCRP levels prevents assessment of treatment response modification.
    • Early trial cessation may lead to overestimation of treatment benefits and underestimation of risks.
    • Reliable cost-effectiveness analysis for rosuvastatin in primary prevention is precluded by early stopping.

    Conclusions:

    • The JUPITER trial's limitations obscure the true benefit-risk profile of rosuvastatin in primary prevention.
    • Societal health policy implications derived from the JUPITER trial remain uncertain due to methodological constraints.
    • Further research is needed to clarify the role of hsCRP and long-term outcomes in statin therapy for primary prevention.